Synthetic peptide corresponding to a region between residues 475 and 525 of human PAF1 (TrEMBL Q9NUU9).
Human controls: Anaplastic Thyroid Carcinoma, Bladder Cell Carcinoma, Breast Carcinoma, Colon Carcinoma, Laryngeal Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Ovarian Carcinoma, Pancreatic Islet Cell Tumor, Skin Melanoma and Small Cell Lung Cancer.
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.09% Sodium Azide
Constituents: 0.1% BSA, Tris buffered saline
Concentration information loading...
Immunogen affinity purified
ab84914 was affinity purified using an epitope specific to Paf1 immobilized on solid support. Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: 1/100 - 1/500. Epitope exposure is recommended. Epitope exposure with citrate buffer will enhance staining.
Likely to work with frozen sections.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
The mammalian PAF1 complex is a multifunctional complex. The PAF1 complex interacts with RNA polymerase II and may be involved in both initiation and elongation, and in histone methylation and RNA processing. Has oncogenic activity in vivo and in vitro.
Belongs to the PAF1 family.
Nucleus. Punctuate distribution throughout the nucleus except in nucleoli and the perinuclear chromatin.